Safety and Immunogenicity of Three Formulations of Vi-CRM197 Vaccine Against S. Typhi in Adults (18-40 Years Old)

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

88 participants

Study Classification

INTERVENTIONAL

Study Start Date

2010-10-31

Study Completion Date

2010-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This trial is aimed to evaluate the safety and immunogenicity profiles of three formulations of Vi-CRM197 conjugate vaccine against S. Typhi in healthy human adults in comparison with the currently licensed Vi polysaccharide vaccine

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Safety and Immunogenicity of Vi-CRM197 Vaccine Against S. Typhi in Adult (18-40 Years Old)

NCT01123941

Typhoid Fever

COMPLETED PHASE1

Safety and Immunogenicity of Vi-CRM197 Vaccine Against S. Typhi in Adults, Children, Older Infants and Infants

NCT01229176

Typhoid Fever

COMPLETED PHASE2

Extension Study of H01_04TP to Evaluate the Booster Response Induced by Vi-CRM197 in Adults

NCT01438996

Typhoid Fever

COMPLETED PHASE2

CVD 909 Vi Prime Boost Study

NCT00326443

Typhoid Fever

COMPLETED PHASE1

Safety and Immunogenicity of a Novel Conjugate Vaccine Against Salmonella Typhi and Salmonella Paratyphi A in Healthy Adults

NCT05613205

Typhoid Fever

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Typhoid Fever

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

NVGH Vi-CRM197 conjugate vaccine 12.5 mcg

1 dose of 0.5 mL containing 12.5 mcg of Vi-CRM

Group Type EXPERIMENTAL

NVGH Vi-CRM197 12.5 mcg

Intervention Type BIOLOGICAL

1 dose of 0.5 mL

NVGH Vi-CRM197 conjugate vaccine 5 mcg

1 dose of 0.5 mL containing 5 mcg of Vi-CRM

Group Type EXPERIMENTAL

NVGH Vi-CRM197 5.0 mcg

Intervention Type BIOLOGICAL

1 dose of 0.5 mL

NVGH Vi-CRM197 conjugate vaccine 1.25 mcg

1 dose of 0.5 mL containing 1.25 mcg of Vi-CRM

Group Type EXPERIMENTAL

NVGH Vi-CRM197 1.25 mcg

Intervention Type BIOLOGICAL

1 dose of 0.5 mL

Typherix

1 dose of 0.5 mL containing 25 mcg of Vi-polysaccharide

Group Type ACTIVE_COMPARATOR

Vi-polysaccharide vaccine

Intervention Type BIOLOGICAL

1 dose of 0.5 mL containing 25 mcg of Vi polysaccharide

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

NVGH Vi-CRM197 12.5 mcg

1 dose of 0.5 mL

Intervention Type BIOLOGICAL

NVGH Vi-CRM197 5.0 mcg

1 dose of 0.5 mL

Intervention Type BIOLOGICAL

NVGH Vi-CRM197 1.25 mcg

1 dose of 0.5 mL

Intervention Type BIOLOGICAL

Vi-polysaccharide vaccine

1 dose of 0.5 mL containing 25 mcg of Vi polysaccharide

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Males and females of age ≥18 to ≤40 years.
2. Individuals who, after the nature of the study have been explained to them, have given written consent according to local regulatory requirements.
3. Individuals in good health as determined by the outcome of medical history, physical examination and clinical judgment of the investigator.
4. Individuals with negative urine screening tests for drug addition (Opiate, Cocaine, Amph/Metamphetamine, Cannabinoides )
5. If women, use of birth control one month before study start, a negative pregnancy test and willingness to use birth control measures for the entire study duration.

Exclusion Criteria

1. Individuals with behavioral or cognitive impairment or psychiatric disease that, in the opinion of the investigator, may interfere with the subject's ability to participate in the study.
2. Individuals with any progressive or severe neurological disorder, seizure disorder or Guillain-Barré syndrome.
3. Individuals who are not able to understand and to follow all required study procedures for the whole period of the study.
4. Individuals with history of any illness that, in the opinion of the investigator, might interfere with the results of the study or pose additional risk to the subjects due to participation in the study.
5. Individuals with known or suspected HIV infection or HIV related disease, with history of an autoimmune disorder or any other known or suspected impairment /alteration of the immune system, or under immunosuppressive therapy including use of systemic corticosteroids or chronic use of inhaled high-potency corticosteroids within the previous 30 days, or were in chemotherapy treatment within the past 6 months.
6. Individuals with a known bleeding diathesis, or any condition that may be associated with a prolonged bleeding time.
7. Individuals with any serious chronic or progressive disease according to judgment of the investigator (e.g., neoplasm, insulin dependent diabetes, cardiac, renal or hepatic disease).
8. Individuals who have any malignancy or lymphoproliferative disorder.
9. Individuals with history of allergy to vaccine components.
10. Individuals participating in any clinical trial with another investigational product 30 days prior to first study visit or intent to participate in another clinical study at any time during the conduct of this study.
11. Individuals who have previously received any vaccines against typhoid fever (either oral live attenuated or injectable vaccines).
12. Individuals who received any other vaccines within 4 weeks prior to enrolment in this study or who are planning to receive any vaccine within 4 weeks from the study vaccine.
13. Individuals who have received blood, blood products and/or plasma derivatives including parenteral immunoglobulin preparations in the past 12 weeks.
14. Individuals who are part of study personnel or close family members to the personnel conducting this study.
15. Individuals with body temperature \> 38.0 degrees Celsius within 3 days of intended study immunization.
16. BMI \> 35 kg/m2.
17. Individuals with history of substance or alcohol abuse within the past 2 years.
18. Women who are pregnant or breast-feeding or of childbearing age who have not used any birth control measure one month prior to study start or do not plan to use acceptable birth control measures, for the duration of the study.
19. Females with history of stillbirth, neonatal loss, or previous infant with anomaly.
20. Individuals who have a previously ascertained or suspected disease caused by S. Typhi.
21. Individuals who have had household contact with/and or intimate exposure to an individual with laboratory confirmed S. Typhi.
22. Any condition which, in the opinion of the investigator may interfere with the evaluation of the study objectives.

Minimum Eligible Age

18 Years

Maximum Eligible Age

40 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes